Baird analyst Joel Beatty lowered the firm’s price target on Acadia Pharmaceuticals to $31 from $40 and keeps an Outperform rating on the shares. The firm removed the negative symptoms of schizophrenia from their model, after the failure of the phase 3 ADVANCE-2 trial of pimavanserin in this indication.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACAD:
- Acadia (NASDAQ:ACAD) Plunges as Pimavanserin Disappoints in Phase 3 Trial
- Acadia Pharmaceuticals should be bought on weakness, says Mizuho
- Australian Stocks: Neuren’s (NEU) Daybue Sales Fail to Impress, Shares Plunge
- Acadia Pharmaceuticals provides FY24 product sales guidance
- Acadia Pharmaceuticals reports Q4 EPS 28c, consensus 30c
